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Abstract
Introduction: JC Virus (JCV), a human polyomavirus, is frequently present in colorectal cancers (CRCs). JCV large T-Ag (T-Ag)
expressed in approximately half of all CRC’s, however, its functional role in CRC is poorly understood. We hypothesized that
JCV T-Ag may mediate metastasis in CRC cells through increased migration and invasion.
Material and Methods: CRC cell lines (HCT116 and SW837) were stably transfected with JCV early transcript sequences
cloned into pCR3 or empty vectors. Migration and invasion assays were performed using Boyden chambers. Global gene
expression analysis was performed to identify genetic targets and pathways altered by T-Ag expression. Microarray results
were validated by qRT-PCR, protein expression analyses and immunohistochemistry. Matching primary CRCs and liver
metastases from 33 patients were analyzed for T-Ag expression by immunohistochemistry.
Results: T-Ag expressing cell lines showed 2 to 3-fold increase in migration and invasion compared to controls. JCV T-Ag
expression resulted in differential expression of several genetic targets, including genes that mediate cell migration and
invasion. Pathway analysis suggested a significant involvement of these genes with AKT and MAPK signaling. Treatment
with selective PI3K/AKT and MAPK pathway inhibitors resulted in reduced migration and invasion. In support of our in-vitro
results, immunohistochemical staining of the advanced stage tumors revealed frequent JCV T-Ag expression in metastatic
primary tumors (92%) as well as in their matching liver metastasis (73%).
Conclusion: These data suggest that JCV T-Ag expression in CRC associates with a metastatic phenotype, which may partly
be mediated through the AKT/MAPK signaling pathway. Frequent expression of JCV T-Ag in CRC liver metastasis provides
further clues supporting a mechanistic role for JCV as a possible mediator of cellular motility and invasion in CRC.
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Introduction
Colorectal cancer (CRC), with ,150,000 new cases per year, is
the third most frequent malignant disease, and with ,50,000
deaths, constitutes the second leading cause of cancer mortality
among men and women in the United States [1]. Mortality in
CRC is usually caused by metastatic disease. Despite increasing
efforts to diagnose CRC at an early stage with screening programs,
more than 25% of patients are still diagnosed with metastatic
disease, and an additional 25% eventually develop metastases.
Unfortunately, the molecular mechanisms underlying the devel-
opment of metastasis are poorly understood [2].
The assumption that viruses may be involved into the multistep
process of carcinogenesis has a long history, and it is well accepted
that 15–20% of cancers can be linked to chronic viral infections
[3]. Most of the evidence comes from human papillomavirus and
its role in cervical cancer, hepatitis B virus in hepatocellular
carcinoma, and Epstein-Barr virus in lymphoproliferative diseases,
Burkitt’s lymphoma and nasopharyngeal carcinoma [3,4]. Al-
though there is convincing data to suggest a carcinogenic role for
polyomaviruses in animal models, their role in the causation of
human cancer is controversial in spite of accumulating evidence
from various experimental studies [5,6]. In the present study, we
have investigated the role of human JC polyomavirus (JCV), which
is known to cause progressive multifocal leucoencephalopathy and
has also been frequently found in multiple gastrointestinal cancers
including CRC, implying an oncogenic function in humans [7,8].
JCV is a 5.13 kb, nonenveloped, double stranded, and closed
circular DNA virus, which encodes 3 viral capsid proteins (VP1,
VP2 and VP3), an agnoprotein, small (t-Ag), and large (T-Ag)
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transforming antigens. JCV T-Ag has a considerable sequence
homology with T-Ag’s of BKV and SV40. T-Ag is a multifunc-
tional oncoprotein, which has the ability to bind and break DNA,
and has helicase and ATPase activities [8]. Additionally, through
direct protein-protein interaction, it can inactivate the key tumor
suppressor proteins p53 and pRb, deregulating the cell cycle
checkpoints and avoiding p53-mediated pro-apoptotic activity [8].
T-Ag may control cellular proliferation by deregulating the Wnt-
signaling pathway through stabilization of b-catenin [9,10].
Moreover T-Ag interacts with the IGF-IR signaling system, which
contributes to cell transformation [11].
More than 30 years ago the carcinogenic potential of JCV was
suggested in a hamster model [12,13]. In recent years, several
studies have been performed to evaluate the role of JCV in
humans. The seroprevalence for the JCV viral capsid protein-1 in
the adult population has historically been shown to be about 60–
90%, although recent studies provide new evidence that the
prevalence of JCV may be somewhat lower than that reported
previously [14,15]. Since JCV Mad-1 DNA can be found
throughout the gastrointestinal tract the expression of T-Ag
protein is believed to be a more suitable method for understanding
oncogenic role of JCV in human cancers [16]. Although few
groups have failed to detect JCV T-Ag expression in tumors, the
majority of studies have provided increasing evidence for the
expression of JCV T-Ag in CRC [17]. A recent study from our
laboratory demonstrated that ,50% of patients with CRC express
T-Ag protein, and that T-Ag expression was exclusively present
only in neoplastic colonic cells, but was never expressed in normal
colonic mucosa [18,19]. Further, in one of our earliest experiments
we reported that JCV can induce chromosomal instability (CIN) in
CRC cells [20]. Analysis of different tumor subtypes showed a
clear association between JCV T-Ag expression and both CIN and
the CpG island methylator phenotype in CRCs [19].
Recently, studies have shown that different DNA viruses may
participate in the regulation of tumor cell invasion and migration
to induce a metastatic phenotype. For instance, the E2 oncogene
encoded by HPV, and the LMP1 oncoprotein of EBV virus,
enhance cellular invasion through up-regulation of matrix-
metalloproteinase-9 (MMP-9) [21]. Also, HBx protein of HBV
as well as LMP1 can down-regulate E-cadherin and promote
cellular motility by reducing cellular adhesion [22].
In view of the data on human oncogenic viruses, we hypothesized
that JCV oncogenic proteins, in particular T-Ag, might mediate
migration and invasion and contribute to malignant behavior in
CRC. To address this hypothesis, we established an in vitroCRC cell
model where we generated stable clones of JCV T-Ag-expressing
lines. We first determined migration and invasion ability of the T-
Ag expressing cells. Next, we performed global gene expression
profiling studies to identify specific genetic targets and molecular
pathways that may regulate T-Ag-induced changes in cellular
motility. Herein, we demonstrate that JCV T-Ag transfection in
CRC cells is associated with increased malignant behavior that in
part is mediated through PI3K/AKT and MAPK pathways. In
support of these in vitro data we provide evidence that JCV T-Ag
expression is frequently present in CRC liver metastases.
Materials and Methods
Cells Culture and Transfection
Two human CRC cell lines, HCT116 (microsatellite instability or
MSI) and SW837 (microsatellite stable or MSS) were obtained from
the American Type Culture Collection (ATCC, Manassas, VA). Cells
were cultured in IMDM medium (Invitrogen, Rockville MD)
supplemented with 10% fetal bovine serum with 5% CO2 at 37uC.
Cell lines were transfected with full-length JCV-early transcript coding
region cloned into a pCR3 vector (called JCVE, kindly provided by
Dr. Richard Frisque, The Pennsylvania State University, University
Park, PA) or an empty vector as transfection control. JCVE coding
region encodes all 5 transforming proteins including T-Ag, t-Ag and
the three splice variants (T’165, T’136 and T’135) [23–25].
Transfection was performed with Effectene (QIAGEN, Valencia,
CA) using standard protocol with some modifications. Briefly, 24 h
post-transfection, cells were washed and thereafter grown in standard
medium for another 48 h for transient transfection experiments.
Alternatively, cells were plated into 6 well plates for stable transfection
following selection with 600–1000 mg/ml of G418. Stable clones were
maintained in 200 mg/ml G418. JCV T-Ag expression was regularly
monitored by RT-PCR or Western immunoblotting. Wherever
indicated, the cells were treated with the selective PI3K inhibitor
LY294002 (Cell Signaling, MA) at a concentration of 25 mM or the
selective MEK1/2 inhibitor- U0126 (Cell Signaling, MA) at a
concentration of 10 mM. Both LY294002 and U0126 stocks were
prepared at 10 mM concentration and stored at 220uC until used.
Primary CRC and Liver Metastasis Specimens
To study the JCV T-Ag expression in both primary tumors and
CRC metastasis, we obtained 33 pairs of matching sporadic
metastatic primary CRCs tissues and corresponding liver metas-
tasis specimens from the same patients collected consecutively at
Okayama University Hospital, Okayama, Japan. All patients
provided written informed consent, and the study was approved by
institutional review boards. Clinical and demographical data of the
patients are presented in Table 1.
Microarray Analysis
Microarray gene expression analyses were performed on JCV T-
Ag expressing cells and control cell lines. Cells were harvested at 70–
80% confluency. Total RNAwas isolated using the RNeasy mini-kit
(QIAGEN, Valencia, CA) and amplified using Illumina’s TotalPrep
RNA Amplification Kit. RNA integrity was assessed using the
Agilent 2100 Bioanalyzer. Labeled cRNA was hybridized overnight
to Human HT-12 V3 chips, washed, and scanned on an Illumina
BeadStation-500. Illumina’s BeadStudio version 3.1 was used to
generate signal intensity values from the scans, subtract background,
and scale each microarray to the median average intensity for all
samples (per-chip normalization). The data were transferred to
GeneSpring GX7.3 (Agilent Technologies, Santa Clara, CA) and
after normalization of data from T-Ag transfected cells with vector
control cell lines, unsupervised analysis were performed using the
following criteria: a) transcripts must be detected in at least one
sample (p,0.01)–PALO and b) must demonstrate at least 1.5-fold
up- or down-regulated expression from the median intensity in at
least one sample–1.5xUDALO. Ingenuity pathway analysis (IPA)
(Ingenuity Systems, Inc. CA, USA) was performed to analyze and
categorize differentially expressed genes into different functional
pathways. To validate the reproducibility of these data we
performed semi-quantitative and quantitative Power SYBRgreenH
PCR amplifications from 2 independent passages of vector (V) and
T-Ag transfected cells prior to analyzing gene expression results.
Real Time and Reverse Transcription PCR
For reverse transcription-PCR (RT-PCR), total RNA was
extracted from frozen cell pellets with the RNeasy mini-kit
(QIAGEN, Valencia, CA). RNA was reverse transcribed to cDNA
from 1 mg of total RNA using random hexamers and Advantage
RT-for PCR Kit (Clontech Laboratories, CA). For the determi-
nation of JCV expression in the transfected cell lines, we used the
previously published JEX primers [26] and TaqMan customized
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primers that specifically detect JCV T-Ag mRNA sequences.Pri-
mer sequences and condition are listed in the Table S1.
Western Immunoblotting
Pellets from T-Ag expressing and control cells were lysed in
buffer containing 0.5 M Tris pH 6.8, 80% glycerol, 1.2 g sodium
dodecyl sulfate and 0.5 M EDTA. Heat-denaturated cell lysates
were subjected to electrophoresis on 10% denaturing polyacryl-
amide gels and proteins transferred to PVDF membranes
(Amersham HybondTM-P, GE Healthcare). The blots were probed
with appropriate dilutions of primary and secondary antibodies
(horseradish peroxidase-conjugated IgG). Signal detection was
Table 1. JCV T-Ag expression in primary colorectal cancers and liver metastasis in correlation with clinico-pathological
characteristics.
Demographic data Total n (%) Primary CRC Liver metastasis
T-Ag positive n(%) T-Ag negative n(%) p-value T-Agpositive n(%) T-Agnegative n(%) p-value
All cases 33 (100) 31 (94) 2 (6) 24 (73) 9 (27)
Sex
Female 15 (45) 14 (93) 1 (7) NS 11 (73) 4 (27) NS
Male 18 (55) 17 (92) 1 (6) 13 (72) 5 (28)
Age (years)
Mean age 6 SD 60.8612.6 61.6611.9 48.5623.3 NS 63.7611.2 52.8613.5 0.026
,65 16 (48) 15 (94) 1 (6) NS 10 (63) 6 (37) NS
$65 17 (52) 16 (94) 1 (6) 14 (82) 3 (18)
Localization
Proximal 10 (30) 9 (90) 1 (10) NS 7 (70) 3 (30) NS
Distal 23 (70) 22 (96) 1 (4) 17 (74) 6 (26)
Cecum 1 (3) - - - -
Ascending 6 (18) - - - -
Transverse 3 (9) - - - -
Descending 2 (6) - - - -
Sigmoid 9 (27) - - - -
Rectum 12 (36) - - - -
Differentiation
Moderate 27 (82) 26 (96) 1 (4) NS 20 (74) 7 (26) NS
Well diff. and mucinous 6 (18) 5 (83) 1 (17) 4 (67) 2 (33)
Lymphnodemetastasis
N0–N1 21 (64) 19 (91) 2 (9) NS 15 (71) 6 (29) NS
N2–N4 12 (36) 12 (100) 0 (0) 9 (75) 3 (25)
N0 2 (6) - - - -
N1 19 (58) - - - -
N2 10 (30) - - - -
N3 1 (3) - - - -
N4 1 (3) - - - -
Stage at primary tumoroperation
II–III (no liver metastasis) 10 (30) 9 (90) 1 (10) NS 6 (60) 4 (40) NS
IV (with liver metastasis) 23 (70) 22 (96) 1 (4) 18 (78) 5 (22)
II 1 (3) - - - -
III 9 (27) - - - -
IV 21 (64) - - - -
Local recurrence 2 (6) - - - -
Time to livermetastasis surgery
Mean months 6 SD 9.1612.5 8.4611.5 20628.3 NS 6.268.7 16.8617.7 0.027
Stage II–III 19.3612.0 - - 14.869.6 26.0613.3 NS
Stage IV 5.3610.2 - - 4.166.4 9.4618.3
NS: non-significant (p.0.05) using where appropriate Fishers exact test or unpaired t-test.
doi:10.1371/journal.pone.0008146.t001
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performed following exposure of the membranes to the ECL
reagent (AmershamTM, GE Healthcare) and final visualization
using the Storm imaging system. Following primary antibodies
were used for western immunoblotting: mouse monoclonal
antibody cocktail against JCV T-Ag (clones PAb2003, PAb2023,
PAb20024, PAb2030, PAb2001, PAb2000 kindly provided by Dr.
R. Frisque [27,28]) at 1:50 dilution; rabbit antibodies (Cell
Signaling, MA) at a dilution range of 1:500 to 1:1000: phospho-
AKT (Ser473), AKT, phospho-p44/42 MAPK (Thr202/Tyr204),
p44/42 MAPK; mouse anti-b-actin antibody (Clone AC-15; at
dilution of 1:32000). Secondary goat anti-mouse (sc-2005) and
goat anti-rabbit (sc-2004) antibodies were used at a dilution of
1:5000 with 1 h incubation (Santa Cruz, CA).
Migration and Invasion Assays
In vitro migration and invasion assays were performed using
Boyden chambers (BD Biosciences, Bedford, MA) with 8-mm-pore
size membranes with Matrigel (for invasion assays) or without
matrigel (for migration assays). Briefly, 5 or 106104 cells were
suspended in 500 ml of serum-free medium in the absence or
presence of various selective inhibitors. Complete medium
containing FBS was added to the bottom wells of the plate.
Thereafter the plates were incubated for 72 h at 37uC in 5% CO2.
After incubation, non-migrated cells were removed from the upper
surface of the chamber with a cotton swab. Migrated/invaded cells
were stained either with Diff-QuickTM stain or DAPI for nuclear
DNA in an immunofluorescence assay. The images from at least 4
representative fields of each membrane were quantitatively
measured with ImageJ software (NIH, USA). Each experiment
was repeated at least 3 times to confirm the reproducibility of data.
Cell Proliferation Assays
Proliferations analysis were performed with calorimetric Cell
Proliferation ELISA, BrdU kit (Roche Diagnostics, Indianapolis,
IN). Briefly, equal amount of the cells were cultured in 96-well
plates. After 72 h, BrdU was added to the wells for labeling of
proliferating cells. After 4 h incubation the cells were fixed and
peroxidase-conjugated anti-BrdU antibody was added to the cells.
BrDU incorporation in proliferating cells was quantitatively
determined using a standard microplate reader.
Immunofluorescence
Cells were grown on glass cover slips placed inside 24-well plates.
Cells were washed with PBS, fixed with 4% formaldehyde,
permeabilized with 0.1% Triton X-100 for 5 min, and blocked with
10% goat serum (Zymed, San Francisco, CA) for 30 min. The cells
were subsequently incubated with appropriate dilutions of primary
antibodies overnight, followed by 1 h incubations with fluorescein-
conjugated secondary antibodies (Alexa FluorH 594 goat anti-mouse
IgG (Invitrogen, OR)). Finally, the cover slips were sealed with
ProLongH Gold with DAPI (Invitrogen, OR) and visualized using an
AxioSkop2 multichannel epifluorescence microscope and images
acquired using AxioVision software (CarlZeiss Inc. Thornwood, NY).
Immunohistochemistry
Staining for JCV T-Ag was performed on 4 mm paraffin-
embedded CRC and metastasis tissue sections as described
previously[18,19]. Slides were incubated overnight with primary
mouse monoclonal antibody against SV40 T-Ag, which cross
reacts with JCV T-Ag (clone PAb416, 1:40 dilution, Calbiochem,
CA) followed by incubation in Dako EnVisionTM labeled polymer
(Dako Sytometion Inc., Carpinteria, CA). Staining was developed
by reaction with diaminobenzide (DAB) and counterstained with
hematoxylin. JCV-inoculated hamster brain tumor tissue (kindly
provided by Dr. Kamel Khalili, Temple University, Philadelphia,
PA) was used as a positive control for JCV-specific staining. Brown
chromogen nuclear complexes indicated T-Ag expression, which
was evaluated by 2 independent examiners (AL and AG) who were
blinded to the clinical data.
Statistical Analysis
All data were analyzed using SPSS 11.5 (Chicago, IL, USA) and
Graph Pad Prism 4.0 (San Diego, CA, USA) statistical software.
The differences between two groups were analyzed using Student’s
t-tests or where appropriate Fisher’s exact test. Differences
between more than two groups were analyzed using repeated
measures ANOVA and Bonferroni’s multiple comparisons as a post
hoc test. Two sided p-values of ,0.05 were regarded significant.
Results
JCV T-Ag Was Expressed at Both mRNA and Protein
Levels in Transfected Cells
JCV T-Ag expression is present in approximately 50% of
CRC’s, but its expression in colon cancer cell lines has not been
described previously. At the outset of this study, we analyzed a
subset of CRC cell lines and none of the studied cell lines showed
presence of either JCV T-Ag mRNA or protein expression (data
not shown). To establish an in vitro model for JCV T-Ag
expression, we transfected a JCV T-Ag carrying plasmid into
two prototypic colon cancer cell lines; HCT116, which is a
microsatellite unstable cell line and is representative of Lynch
syndrome colorectal cancers due to an underlying germline
mutation in the DNA mismatch repair gene, MLH1; and
SW837 cells, which are microsatellite stable but harbor mutations
in the p53 tumor suppressor gene (Figure 1A). Both cell lines were
permissive for stable transfection, and maintained T-Ag mRNA
and protein expression after .50 passages as indicated by RT-
PCR and immunoblotting (Figure 1B). Since JCV early
transcript region allows expression of all 5 transforming proteins
including T-Ag, t-Ag and the three splice variants of large T-Ag
(T’165, T’136 and T’135), we performed western immunoblotting
with a cocktail of specific JCV antibodies to determine the
expression of specific early proteins that are expressed in JCVE
transfected colon cancer cell lines. We found that transfection of
JCVE plasmid was predominantly associated with the expression of
JCV T-Ag, suggesting that the other early proteins may not play a
major role in this in-vitro cell culture system in contrast to their
potential role in JCV-induced lytic infection in humans (Figure
S1). Following transfection, we failed to detect any morphological
changes in cellular morphology of JCVE and vector transfected
cells. Immunofluorescence staining with JCV T-Ag specific
antibody further complemented RT-PCR and Western blotting
data, in which T-Ag expression was predominantly nuclear in both
transfected cell lines (Figure 1C).
JCV Transfection Resulted in Increased Invasion and
Migration
To test the hypothesis that one of the mechanisms for JCV T-
Ag-mediated carcinogenesis may be through increased cellular
invasion and migration, we first performed in vitro invasion and
migration assays in T-Ag- and vector-transfected cell lines. As
demonstrated in Figure 2, we observed a significant increase in
both migration (Figures 2A & 2B) and invasion (Figures 2C &
2D) in HCT116 and SW837 cells following T-Ag transfection.
Although there were slight variations between different cell
passages used in independent experiments, T-Ag expressing cells
JCV Mediated Metastasis
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persistently demonstrated increased migration in both HCT116
(mean6 SE, 3.3360.51 fold, p = 0.023) and SW837 cells
(3.8460.54 fold, p = 0.02) when the results were normalized to
vector transfected control cells. We also observed a pronounced
increase in invasion in HCT116 (4.7861.03 fold, p = 0.043) and
SW837 cells (4.6361.45 fold, p = 0.033) following T-Ag transfec-
tion. Since changes in malignant phenotype may partly relate to
changes in proliferation, we performed proliferation assay and
found no difference in proliferation between JCV T-Ag expressing
and vector transfected control HCT116 cells, and a small increase
in proliferation in SW837 cells (data not shown).
JCV Transfection Modulated Expression of Several
Metastasis Associated Genes in AKT and MAPK Pathways
Next, in order to further evaluate potential genetic targets
and molecular pathways that might mediate increased migration
and invasion in T-Ag expressing CRC cell lines, we performed
global gene expression profiling in T-Ag transfected and vector
transfected cell lines. In order to narrow down a subset of
plausible genes that might mediate cellular migration and
invasion, we performed unsupervised clustering analysis and
selected a group of 5559 genes from a total of 48803 genes that
were more than 1.5 fold significantly up- or down-regulated in
at least one of the cell lines as described in the Methods
(Figure 3A). Next, using Ingenuity pathway analysis software,
we discovered that 529 genes that are involved with cellular
motility were differentially expressed in T-Ag expressing
HCT116 and SW837 cells. Although the two analyzed cell
lines are representative of very different colon cancer subtypes,
further analysis revealed that 43 of 529 differentially expressed
genes were commonly up- and down-regulated in both HCT116
and SW837 cell lines (Figure 3B, 3C & 3D). These data
Figure 1. JCV T-Ag expression in transfected colorectal cancer cells. (A) An illustration of the JCV early transcript region that codes for 5 early
transforming proteins, T-Ag, t-Ag and the 3 splice variants T’165, T’136, T’135. T-Ag is predominant protein expressed after transfection (marked in red).
(B) RT-PCR and Western immunoblotting gel images depicting JCV T-Ag specific mRNA and protein expression in stably transfected cells (indicated as
T-Ag), while no T-Ag expression was observed in control cell lines (V, vector transfected). GAPDH (RT-PCR) and b-actin (WB) were used as loading
controls. (C) Immunofluorescence staining with JCV T-Ag antibody shows nuclear expression of JCV T-Ag in transfected HCT116 and SW837 cells lines.
The images were taken at a final magnification of 6306.
doi:10.1371/journal.pone.0008146.g001
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indicated that very likely, this subset of genes might plausibly be
responsible for increased migration and invasion following T-Ag
transfection. Indeed, upon an independent data analyses, we
identified 74 genes in HCT116, and 108 genes in SW837 cell
line that directly or indirectly associated with AKT and MAPK
signaling pathways (Figure 3E). From a total of 43 up- or
down-regulated migration- and invasion-related genes from
both cell lines, 20 genes specifically participated in AKT or
MAPK signaling pathways (Figure 3F). Details on the
microarray gene list are presented as supplementary data
(Table S2). Based on this analysis, we surmised that alterations
in AKT and/or MAPK signaling pathways may play an
important role in phenotypic changes induced by JCV T-Ag
transfection in CRC cells.
In order to validate microarray gene expression data, we
performed qRT-PCR analysis on a randomly selected subset of
genes that showed significant changes in gene expression in at least
one of the cell lines. As shown in Figure 4A, despite slight
differences in absolute fold-changes in gene expression results
between microarray data and qRT-PCR results, we observed a
strong correlation between both methods.
JCV Transfection Caused Activation of AKT and MAPK
Pathways in Colonic Cells
We next questioned whether T-Ag transfection in CRC cells is
associated with activation of either the AKT or MAPK pathways.
Since MSI CRCs are inherently less metastatic, we performed
these experiments with HCT116 cells, which are MSI-positive and
demonstrated increased migration and invasion following T-Ag
transfection in Boyden chamber assays. First we studied the
changes in gene and protein expression of selected genetic
candidates that are associated with increased migration, invasion
or metastasis in CRC. As shown in the Figure 4B, we observed
significant up-regulation in the mRNA transcripts of MMP9,
CCL5, and NOS3 in T-Ag versus vector transfected HCT116
cells. Only a modest increase in uPA, and no change in AKT
mRNA expression, were observed between vector and T-Ag
transfected HCT116 cells. We then asked whether JCV T-Ag
transfection might lead to activation of AKT and ERK1 and
ERK2. Western immunoblotting revealed increased expression of
phosphorylated AKT (Ser473) and both phosphorylated ERK1
and ERK2 (Tyr 202 and Tyr 204) in T-Ag expressing cells
compared to vector carrying HCT116 cells (Figure 4C). In
Figure 2. JCV T-Ag increases migration and invasion in vitro. Migration and invasion assays were performed in Boyden chambers without and
with Matrigel respectively. Representative images from one of the three independent experiments showing migration (A) and invasion (B) in control
and T-Ag transfected HCT116 and SW837 cell lines (2006magnification). The bar graphs in panels B and D are quantitative determinations of data
obtained using ImageJ cell counter software from 3 independent experiments. As indicated, T-Ag transfection (red and blue bars) showed
significantly increased migration and invasion (p,0.05) in both cell lines.
doi:10.1371/journal.pone.0008146.g002
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concordance with the gene expression data, we found no changes
in total AKT or ERK1/2 protein expression.
AKT/MAPK Pathway Inhibitors Blocked Migration and
Invasion in JCV T-Ag Expressing Cells
We reasoned that if increased migration and invasion in T-Ag
expressing cells was due to the activation of PI3K and MAPK
pathways, specific PI3K/AKT and MAPK pathway inhibitors
should be able to inhibit the migration and invasion potential in
these cells. For these experiments, T-Ag expressing cell lines were
treated with LY294002 and U0126 singly or in combination,
followed by in vitro invasion and migration analyses using Boyden
chambers. As expected, both inhibitors strongly reduced phos-
phorylation of AKT and ERK1/2 when used individually,
however, the effects were additive when were used in combination
(data not shown). As shown in Figure 5, LY294002 and U0126
significantly reduced migration (Figures 5A and B; p,0.001, T-
Ag transfected versus both inhibitors individually or in combina-
tion) and invasion (p,0.001; Figures 5C and D) in HCT116 and
SW837 cells. These data strongly support the concept that JCV T-
Ag may induce migration and invasion, and is regulated through
the PI3K and MAPK pathways.
JCV T-Ag Is Frequently Expressed in Liver Metastasis
To further substantiate our in vitro results, we tested whether
expression of JCV T-Ag might be associated with an increased risk
for metastasis. For these studies, we examined JCV T-Ag
expression in 33 patient using matching pairs of primary sporadic
CRCs and the corresponding liver metastasis. Clinical character-
istics of the patients are presented in Table 1. The majority of the
samples obtained for this study were from patients with distal
CRCs, mostly moderately differentiated, and 70% had stage IV
tumors at the time of the primary tumor resection. Mean follow up
time from primary diagnoses to liver metastasis surgeries was
9.1612.5 months.
Representative examples of JCV T-Ag positive and negative
staining are shown in Figure 6. Normal colonic mucosa
Figure 3. Global gene expression analysis of JCV T-Ag transfected cells. (A) The flow chart represents the strategy used for gene expression
analysis. Using unsupervised analysis we selected 5559 genes. Dendograms in panels B and C illustrate clustering analysis of JCV-T-Ag transfected
cells compared to vector controls. Gene trees are represented on the horizontal axis, while condition trees are represented on the vertical axis. The
color conventions for all maps are as follows: red indicates over-expressed transcripts, blue are under-expressed transcripts, and yellow indicates
transcripts that did not deviate from the controls. Clustering analysis in panel B illustrates Ingenuity pathway analysis which revealed 529 genes that
are involved in regulation of cell motility. Of these, a subset of 43 genes that are specifically involved in migration or invasion and were up- or down-
regulated in both cell lines are shown in panels C (as dendogram) and D (Venn diagram). Of this group of 43 genes, 20 genes that are directly or
indirectly involved in AKT and MAPK pathways were shared between both HCT116 and SW837 cells as shown in panel E (Venn diagram) and panel F
(as a schematic interaction of individual genes with each other). Red indicates up-regulated and green indicates down-regulated genes following T-
Ag transfection (panel F).
doi:10.1371/journal.pone.0008146.g003
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(Figure 6B) as well as liver cells (Figure 6C) showed no T-Ag
staining in comparison to the positive control tissue (Figure 6A).
Unexpectedly, although variable staining intensity was observed,
T-Ag expression was present in 31 (93.9%) primary CRCs
(Figure 6D & 6E; Table 1). Next, upon analysis of T-Ag
expression in liver metastases from these same patients, we found
that 24 (72.7%) of the patients showed JCV T-Ag expression also
in the liver metastasis (Figure 6F). In 6 cases (19%) there was no
T-Ag expression in the liver metastasis, although T-Ag expression
was present in the primary tumor. None of the cases showed T-Ag
positive expression in the liver metastasis if the primary tumor did
not express this oncogene. Subgroup analysis revealed that JCV T-
Ag expression in the liver metastasis was more frequently present
in higher tumor stages and older age, supporting the hypothesis
that JCV expression might be associated with an advanced stage of
disease. Additionally, T-Ag expression in liver metastasis was
associated with a shorter time interval between primary tumor
resection and liver metastasis surgery in patients with stage II–III
disease.
Discussion
This work suggests that JCV infection is capable of mediating
some of the most virulent aspects of tumor behavior in CRC.
Transfection of JCV early transcript region into CRC cells and
subsequent expression of JCV T-Ag induces phenotypic changes
manifested through an increased potential for migration and
invasion. These phenotypic alterations were further associated
with the increased transcription of multiple genes that are likely to
be involved in metastatic behavior, specifically, through the AKT
and MAPK pathways. We also demonstrated that JCV T-Ag
expression is not only present in primary CRCs, but is frequently
present in liver metastases. Additionally, we found a correlation
between JCV T-Ag expression in liver metastasis and more
advanced tumor stage, lending support to our in vitro results, and
suggesting a novel mechanism for the role of T-Ag in the
progression of CRC.
In spite of the evidence suggesting the involvement of JCV in
CRC more than a decade ago [29], the role of JCV in human
cancer is currently poorly understood. An oncogenic role for JCV
has been demonstrated in several animal studies including rodents
and primates (reviewed in [30]), but the lack of an adequate in vitro
model has hampered our understanding of the role of JCV in
human cancer.
Notwithstanding that JCV may have a multitude of effects on
tumor cells, in this study we focused our investigation on
understanding JCV-induced changes in the migration and
invasion of tumor cells. In this study, we intentionally selected
CRC cell lines from both MSS and MSI genetic backgrounds
because T-Ag expression has been shown to correlate with both
Figure 4. Gene expression changes following T-Ag transfection in HCT116 cells. (A) Microarray global gene expression data were validated
in a randomly selected subset of genes by quantitative RT-PCR. Data are represented as the mean fold change normalized to vector cells. As
indicated, there was a tight correlation between microarray and qRT-PCR in each instance. (B) A subset of cancer-metastasis related genes including
MMP-9, uPA, CCL5 and NOS3 showed increased expression following T-Ag transfection in HCT116 cells. (C) Western blotting data indicated increased
phosphorylation of AKT as well as ERK1/2 in T-Ag transfected cells in comparison to control cell lines.
doi:10.1371/journal.pone.0008146.g004
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categories of CRC [19]. We observed that JCV-transfected
HCT116 and SW837 cells gained an increased ability for
migration and invasion. In-vitro Matrigel based methods to study
invasion and migration have been used for decades in laboratory-
based research, and it has been shown that these assays correlate
well with the in-vivo metastatic behavior of the cells [31,32]. Our
data corroborate some of the previous work done on other
oncogenic DNA viruses like HPV, HBV and EBV, where changes
in the modulation of cell adherence, motility, invasion and
interaction with the microenvironment are common features [33].
One can argue that despite the structural and genomic differences
between the DNA viruses, oncogenic viruses target similar tumor
suppressor proteins (i.e., p53 and pRB) to orchestrate their activity.
Along similar lines, there has been a suggestion that the PI3K/
AKT or MAPK signaling pathways may mediate cellular
migration and invasion by oncogenic viruses [34], as we observed
in this study.
Although the role of JCV in malignant behavior has attracted
little attention in the past, in an early experiment, JCV Mad-1
strain induced highly malignant, metastatic neuroblastomas in
hamsters [35]. In another study, Khalili’s group demonstrated that
subcutaneous transplantation of T-Ag expressing cells, but not T-
Ag negative cells, resulted in the development of massive tumors in
experimental animals [36].
Figure 5. PI3K and MAPK pathway inhibitors reduced migration and invasion of JCV T-Ag transfected cells. Migration (panels A and B)
and invasion (panels C and D) were performed using Boyden chambers without or with Matrigel. LY294002 (25 mM) and U0126 (10 mM) were added
to both upper and lower chambers. Cells that invaded through Matrigel, and migrated through the 8 mm pores in the membrane were stained with
DAPI. Cell counting was performed with ImageJ software. Data in bar graphs demonstrate fold changes normalized to vector cells (means6SE)
obtained from 3 independent experiments. Significant inhibition in both migration and invasion was observed in both HCT116 and SW837 cells with
LY294002 and U0126 individually and in combination.
doi:10.1371/journal.pone.0008146.g005
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After obtaining evidence for increased cellular invasion and
migration upon the introduction of JCV T-Ag in colon cancer
cells, we were able to demonstrate that these phenotypic changes
were associated with marked alterations in the expression of a
large number of genes. These results are in line with a previous
study by Nerurkar and colleagues in which the authors have
analyzed gene expression alterations following transfection of a
full-length JCV plasmid into glial cells [37]. Although we observed
overlapping changes in gene expression results between our study
and this previous report, we also noticed other differences
including reduced activation of interferon related genes. Our
observations for differences in gene expression profiles between
HCT116 and SW837 cells following JCVE transfection highlights
the contribution of genetic (mutations, deletions etc) and
epigenetic (methylation of gene promoters) factors that might
mediate JCV-induced gene expression alterations in humans. We
observed that various genes CD44, CCL5, VEGFA, DSCR1,
AURKA, RUNX2 and MMP9 were significantly altered following
JCV T-Ag expression, and prior data supports the role of these
genes in migration and invasion behaviors in CRCs [38]. These
observations further argue against the solitary regulation of
individual genes by T-Ag, and rather support a broader role for
this oncogene in mediating the expression of multiple targets that
cumulatively impact the metastatic phenotype in CRC.
Ingenuity pathway analysis of data from differentially expressed
genes in T-Ag transfected cells identified a subset of genes that are
associated with cellular migration and invasion through the AKT
and MAPK signaling pathways. It was recently shown that
activation of ERK1/2 is a predictor of a poor prognosis in CRC,
and strongly associates with K-RAS mutations [39]. AKT
expression has also been associated with progression in colon
carcinogenesis, but it has not been shown to be associated with
prognosis [40]. However, key mechanistic role has been shown for
AKT2 in CRC metastasis [41]. In this study, we could
demonstrate that transfection of JCV T-Ag into the MSI-positive
HCT116 cell line results in increased expression of both
phosphorylated AKT and ERK1/2 proteins, supporting the
interpretation that JCV T-Ag expression supports an AKT-
mediated metastatic phenotype in CRC cells.
Several recent studies have highlighted the importance of AKT
and MAPK pathways in JCV biology. For instance, JCV entry
into the cell requires tyrosine kinase activity and JCV T-Ag
Figure 6. JCV T-Ag expression in primary CRC tumors and in liver metastasis. Staining was performed with Pab416 antibody against SV40
T-Ag with cross reactivity to JCV T-Ag. Images were obtained at 1006and 4006magnification (as shown in the insets within each photomicrograph)
(A) Positive control staining from hamster brain tissue infected with JC virus shows strong nuclear T-Ag expression. Normal colonic mucosa (B) and
liver hepatocytes (C) showed no JCV T-Ag expression and were used as negative controls with each staining. (D) A representative example of a CRC
and colonic mucosa with no T-Ag expression. (E) A photomicrograph indicating strong nuclear T-Ag expression in invasive primary colonic tumor (F)
The image illustrates T-Ag-specific expression in liver metastasis in cancer cells but no expression in surrounding normal liver hepatocytes.
doi:10.1371/journal.pone.0008146.g006
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activates the MAPK pathway through phosphorylation of ERK1/
2 [42]. In medulloblastoma cell lines, prolonged activation of AKT
positively correlates with the presence of JCV T-Ag expression
[11]. From another perspective, increases in TGFb as well as ERK
expression have been shown to be involved in JCV multiplication,
an effect that can be reversed upon treatment with PD98059 or
U0126 [43]. We made similar observations as treatment with
PI3K/AKT and MAPK pathway inhibitors strongly inhibited
JCV T-Ag-associated migration and invasion, implicating the
involvement of these pathways. Although we were able to identify
the involvement of the AKP/MAPK pathway in JCV-mediated
motility in colon cancer cells, our study did not address the specific
roles of individual signaling molecules in these pathways. One of
the unique features of our study is that we transfected complete
JCV early transcript coding region, which associates with the
expression of all 5 potential transforming including novel T-Ag
splice variants previously shown by Frisque’s group [24]. In this
study, we predominantly observed expression of JCV T-Ag only in
both transfected cell lines. Although we cannot exclude with
certainty the role of t-Ag and other T’- proteins, based upon our
results it is reasonable to speculate that T-Ag may be the primary
mediator of a metastatic phenotype in colon cancer cells, and some
of these effects may directly or indirectly be influenced by the
activation of AKT/MAPK pathways [44,45]. Nonetheless, future
studies are required to better appreciate the functional conse-
quences of changes in expression of MAPK/AKT pathway genes,
and to determine whether these alterations are a direct
manifestation of T-Ag transfection.
To evaluate possible clinical relevance of our in vitro data we also
examined T-Ag expression in 33 sporadic CRC tumors and the
associated liver metastases. Surprisingly, more than 90% of the
tumors expressed JCV T-Ag, which is greater than what has been
previously described in sporadic CRCs [19]. We acknowledge the
possibility that one of the reasons for a higher frequency of T-Ag
expression in this collection of tumors might due to selection bias
of the tumors from known metastatic CRCs, compared to the
unselected collections in previous publications. In addition, we did
not have access to clinical data for the chemotherapy regimens
prior to surgery, which could potentially select for JCV T-Ag
expressing cells. Due to the limited availability of the clinical tissue
specimens, we were unable to evaluate AKT and ERK1
expression in the primary CRCs and liver metastases tissues -
future studies are required to address these questions. Nonetheless,
we believe that we have analyzed a reasonable collection of
primary tumors and liver metastases and for the first time we show
not only that JCV T-Ag is expressed in primary CRC tumors, but
also is frequently found in their liver metastases at a much higher
frequency than what have been previously shown for non-
metastatic sporadic CRCs [10,19]. Although our data for T-Ag
expression in liver metastases from patients with CRC will require
independent validation in future prospective studies, currently,
these results permit us to draw several conclusions. First, together
with the in vitro data, these data indicate that JCV T-Ag expression
in CRC may be associated with metastatic cellular behavior.
Second, the presence of T-Ag expression in primary CRC and the
liver metastases raises the possibility of integration of JCV into the
cancer cell genome, as the origin of these cells is presumably from
putative cancer stem cells.
In summary, this study suggests a novel role for JCV T-Ag in
human CRC. We demonstrate that transfection of JCV early
transcripts into cancer cells could increases migration and invasion
through up-regulation of metastasis-associated genes. Increased
expression of phosphorylated AKT and ERK1/2 and the reversible
effect of PI3K/AKT and MAPK pathway inhibitors imply, at least
in part, the involvement of PI3K/AKT and MAPK pathways.
Detection of JCV T-Ag expression in primary CRCs and their
metastases suggests a novel role for JCV T-Ag in metastasis during
the late stages of CRC. Based on this data, we propose that JCV T-
Ag may play a broader role than previously thought, and may be
mechanistically involved in the late stages of these tumors.
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